ALX Oncology Publishes Encouraging Phase 2 Data for Gastric Cancer Drug

ALX Oncology announced the publication of Phase 2 clinical data for evorpacept in Nature Medicine. The investigational CD47-blocker showed encouraging efficacy and manageable safety in patients with previously treated HER2-positive advanced gastric or gastroesophageal junction cancer. This development suggests a potential new treatment option for a challenging cancer type, warranting further investigation.